嵌合抗原受体调节性T细胞免疫疗法在器官移植中的应用  

Application of chimeric antigen receptor-regulatory T cell immunotherapy in organ transplantation

作　　者：吴俣 李佩璐[2] 葛军 蒋廷亚[1] Wu Yu;Li Peilu;Ge Jun;JiangTingya(AlloDx Biotech Co.,LTD,Shanghai 215000,China)

机构地区：[1]奥根诊断(AlloDx),上海215000 [2]江苏大学生命科学研究院

出　　处：《器官移植》2020年第5期547-552,共6页Organ Transplantation

基　　金：国家自然科学基金(31900722)。

摘　　要：调节性T细胞(Treg)是对机体进行免疫负调控的一类T细胞亚群,具有抑制排斥反应的作用。通过嵌合抗原受体(CAR)技术对Treg进行特异性的改造,可以成功地将供体特异性抗原嵌合到Treg表面,从而实时调节机体的免疫功能,为诱导免疫耐受提供了一种新颖而有前景的治疗选择。本文综述了Treg在免疫相关疾病中的研究、CAR-Treg技术实现的主要难点及其在诱导器官移植免疫耐受方面的研究进展,展望了CAR-Treg在器官移植领域应用的机会与挑战。Regulatory T cell(Treg)is a subset of T cells that negatively regulates immunity and has the function of inhibiting rejection.The specific modification of Treg by chimeric antigen receptor(CAR)technology can successfully chime donor-specific antigen onto the surface of Treg,thus regulating the immune function of the body in a real-time manner.It provides a novel and promising therapeutic option for inducing immune tolerance.In this article,research progresses on Treg in immune related diseases,main difficulties in the realization of CAR-Treg technology and its role in inducing transplantation immune tolerance were reviewed,and the opportunities and challenges of CAR-Treg application in the field of organ transplantation are prospected.

关 键 词：免疫抑制剂 调节性T细胞(Treg) 嵌合抗原受体(CAR) 抗体介导的排斥反应(AMR) 移植免疫耐受 供体特异性抗体(DSA) 人类白细胞抗原(HLA) 移植物抗宿主疾病(GVHD) 

分 类 号：R617[医药卫生—外科学] R392.4[医药卫生—临床医学]